Lasgrain(Lasmiditan)
Therapeutic Group: Drugs of Nervous System, Anti Migraine
Lasgrain 50: Each tablet contains Lasmiditan Hemisuccinate INN equivalent to Lasmiditan 50 mg.
Lasgrain 100: Each tablet contains Lasmiditan Hemisuccinate INN equivalent to Lasmiditan 100 mg.
Description
Lasmiditan is a serotonin (5-HT) 1F receptor agonist. It binds with high affinity to the 5-HT1F receptor. It presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT1F receptor; however, the precise
mechanism is unknown.
Indications
Lasmiditan is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use: It is not indicated for the preventive treatment of migraine.
Dosage & Administration
The recommended dose of Lasmiditan is 50 mg, 100 mg, or 200 mg taken orally, as needed. No more than one dose should be taken in 24 hours and Lasmiditan should not be taken unless the patient can wait at least 8 hours between dosing and driving or operating machinery. A second dose of Lasmiditan has not been shown to be effective
for the same migraine attack. The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established. Lasmiditan may be taken with or
without food. Administer tablets whole; do not split, crush, or chew
Side Effects
The common side-effects of Lasmiditan include-dizziness, fatigue, paresthesia, sedation etc.
Precautions
1. Driving Impairment: Advise patients not to drive or operate machinery until at least 8 hours after taking each dose of Lasmiditan.
2. Central Nervous System (CNS) Depression: Lasmiditan may cause CNS depression and should be used with caution if used in combination with alcohol or other CNS
depressants.
3. Serotonin Syndrome: Reactions consistent with serotonin syndrome were reported in patients treated with Lasmiditan. Discontinue Lasmiditan if symptoms of serotonin syndrome occur.
4. Medication Overuse Headache: Detoxification may be necessary
Use in Pregnancy & Lactation
Pregnancy: Lasmiditan may cause fetal harm when administered to a pregnant woman and it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: There are no data on the presence of Lasmiditan in human milk, the effects of Lasmiditan on the breastfed infant, or the effects of Lasmiditan on milk production
Drug Interaction
1. Lasmiditan may further lower heart rate when administered with heart rate lowering drugs.
2. Avoid concomitant use with P-gp and Breast Cancer Resistant Protein (BCRP) substrates.
Use in special population
Pediatric use: Safety and effectiveness of Lasmiditan has not been established in pediatric patients.
Geriatric use: Start at the low end of the dosing range.
Hepatic impairment: No dose adjustment is needed for patients with mild or moderate hepatic impairment. Use of Lasmiditan in severe hepatic impairment is not
recommended.
Over Dose
n the event of overdose, Lasmiditan should be discontinued and general supportive treatment given until clinical toxicity has been diminished or resolved.
Storage
Do not store above 30 º C. Keep away from light and out of the reach of children
Commercial Pack
Lasgrain 50 : Each box contains 1 blister strip of 10 tablets.
Lasgrain 100 : Each box contains 1 blister strip of 4 tablets.
